Curetis, Beijing Clear Biotech expand strategic collaboration
Curetis, a developer of next-level molecular diagnostic solutions, has announced that it has significantly expanded its strategic collaboration with Beijing Clear Biotech (BCB) for the exclusive distribution of the Unyvero A50 Platform and Unyvero A50 Application Cartridges in Greater China. The parties have amended their exclusive international distribution agreement, originally signed in September 2015, to expand the term of the Agreement from five to eight years from the first regulatory approval in China. The amended agreement has also expanded the total commitment of BCB for cumulative minimum purchases to more than 360 Unyvero A50 Systems from 260 Systems previously and over 1.5 million Unyvero Application A50 Cartridges from about 550,000 Cartridges previously for the duration of the Agreement. This minimum commitment would indicate potential revenues to Curetis of over EUR 30 million annually in years six to eight of commercialization in China in addition to potential cumulative revenues of more than EUR 60 million for years one to five of commercialization in China as agreed upon previously.